Please login to the form below

Not currently logged in

Endo to collaborate with India-based CRO GVK Biosciences

Will develop small molecule against undisclosed target in pain

GVK BiosciencesEndo has entered a deal with the India-based contract research organisation (CRO) GVK Biosciences to develop small molecules targeting an unnamed protein.

As part of the deal, financial details of which remain undisclosed, GVK Biosciences will deliver a clinical candidate for Endo to then develop and commercialise.

The collaboration is the first to come from what GVK Biosciences calls its Early Discovery Assets (EDA) programme, which is seeing the company develop a portfolio of discovery project assets for potential early stage partnering.

A specific indication for the Endo collaboration was not given, although the EDA portfolio is focused around pain and inflammation, which is in line with Endo's specialities of pain, urology/oncology and endocrinology.

According to GVK, the EDA programme involves the CRO developing these assets to a stage where they can demonstrate value as a treatment, before looking for partnership opportunities to continue development.

Manni Kantipudi, CEO of GVK Biosciences, said: “We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations.

“This collaboration also confirms the value of our differentiated EDA concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates.”

The collaboration with Endo comes in the same month that GVK Biosciences entered a deal with another US-based pharma company.

In early January, it agreed to partner with Onconova Therapuetics to develop two of Onconova's discovery targets in cancer using GVK's discovery platform.

The CRO also has an arrangement with Astellas Pharma to provide the Japan-based pharma company with access to its 'structure activity relationship' (SAR) database, which includes data for more than 5.1 million compounds.

29th January 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...